Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the ...

(NYSE: CALX) today announced the next generation of the Calix Broadband Platform, fully evolved for agentic AI and purpose-built to address the workflow, data, security, and insight requirements of ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average ...

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after market close. The Zacks Consensus Estimate for the to-be-reported ...

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

BioMarin will host a conference call and webcast to discuss third quarter 2025 financial results today, Monday, October 27, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on ...

After pioneering haptic gloves for virtual reality, Tokyo-based startup Diver-X is taking aim at one of the most familiar computer tools: the ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Lea Uradu, J.D., is a Maryland state registered tax preparer, state-certified notary public, ...